Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811882 | PMC |
| http://dx.doi.org/10.3909/riu0782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.
Nucl Med Biol
December 2024
Life Sciences Division, TRIUMF, BC V6T 2A3 Vancouver, British Columbia, Canada; Department of Chemistry, University of British Columbia, V6T 1Z1 Vancouver, British Columbia, Canada.
Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use. The availability of these radionuclides is often constrained by the intricate production processes and purification, as well as regulatory and logistical challenges.
View Article and Find Full Text PDFInsights of BDAPbI-Based Flexible Memristor for Artificial Synapses and In-Memory Computing.
ACS Omega
November 2024
Department of Physics, School of Energy Technology, Pandit Deendayal Energy University, Gandhinagar 382426, India.
Inspired by brain-like spiking computational frameworks, neuromorphic computing-brain-inspired computing for machine intelligence promises to realize artificial intelligence (AI) while reducing the energy requirements of computing platforms. In this work, we show the potential of advanced learnings of butane-1,4-diammonium based low-dimensional Dion-Jacobson hybrid perovskite (BDAPbI) memristor devices in the realm of artificial synapses and neuromorphic computing. Memristors validate Hebbian learning rules with various spike-dependent plasticity within a 10 ± 2 ms time frame, reminiscent of the human brains under flat and bending conditions (∼5 mm radium).
View Article and Find Full Text PDFTargets for improving prostate tumor response to radiotherapy.
Eur J Pharmacol
January 2025
Department of Urology, Yantaishan Hospital, Shandong, 264000, China. Electronic address:
Article Synopsis
- * Early treatment focuses on localized cancer, while later-stage treatments deal with recurrent or advanced forms of the disease, utilizing therapies like radium-223 and the recently approved 177Lu-PSMA-617.
- * Ongoing research is exploring ways to make prostate tumors more responsive to radiotherapy by targeting mechanisms of resistance, such as DNA repair and immune evasion, to improve treatment effectiveness and reduce side effects.
Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy.
Sci Rep
November 2024
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Article Synopsis
- Multiple myeloma (MM) is a type of cancer that starts in plasma cells and is divided into two main genetic subtypes: hyperdiploid and non-hyperdiploid.
- This study used human myeloma cell lines (HMCLs) to investigate protein expression of cell surface markers relevant to MM treatment, finding that some markers were consistently expressed while others showed variation.
- Analysis revealed that some HMCLs closely matched the characteristics of patient-derived samples, highlighting the need for careful selection of cell lines to best model MM for research and therapeutic purposes.
An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors.
Radiother Oncol
January 2025
Department of Radiation Oncology, University of Rochester, Rochester, NY, USA.
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!